Brodalumab
- Generic Name
- Brodalumab
- Brand Names
- Siliq, Kyntheum
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1174395-19-7
- Unique Ingredient Identifier
- 6ZA31Y954Z
- Background
Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
- Indication
Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
Brodalumab in the Treatment of Immune-Related Adverse Events
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Brian Henick, MD
- Target Recruit Count
- 11
- Registration Number
- NCT06673329
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 394
- Registration Number
- NCT05132231
- Locations
- 🇨🇦
CARE Site 52, Saint-Charles-Borromée, Quebec, Canada
🇨🇦CARE Site 42, Calgary, Alberta, Canada
🇨🇦CARE Site 26, Calgary, Alberta, Canada
Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 4
- Registration Number
- NCT04979520
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 244
- Registration Number
- NCT04340076
- Locations
- 🇳🇱
Amphia Hospital, Breda, Netherlands
🇳🇱Radboudumc, Nijmegen, Netherlands
🇳🇱Máxima Medisch Centrum, Veldhoven, Netherlands
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT04305327
- Locations
- 🇪🇸
LEO Pharma Investigational Site, Valencia, Spain
🇩🇪LEO Pharm Investigational Site, Mainz, Germany
Adjusted Brodalumab Dose Compared with Standard Brodalumab Dose in Subjects with Moderate-to-severe Plaque Psoriasis and ≥120 Kg Body Weight
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 385
- Registration Number
- NCT04306315
- Locations
- 🇬🇧
LEO Pharma Investigational Site, Shipley, United Kingdom
An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Rockefeller University
- Registration Number
- NCT04249713
- Locations
- 🇺🇸
Rockefeller University Hospital, New York, New York, United States
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT04149587
- Locations
- 🇨🇦
Bausch Site 002, Montréal, Manitoba, Canada
🇨🇦Bausch Site 001, Winnipeg, Manitoba, Canada
🇨🇦Bausch Site 014, North Bay, Ontario, Canada
Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 10
- Registration Number
- NCT03960268
- Locations
- 🇺🇸
Rockefeller Unviersity, New York, New York, United States
Treatment of Moderate Hidradenitis Suppurativa
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Florida Academic Dermatology Centers
- Target Recruit Count
- 20
- Registration Number
- NCT03910803
- Locations
- 🇺🇸
Florida Academic Centers Research and Education, LLC, Coral Gables, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.